Imatinib 100 & 400 Zydus 100 mg, 400 mg Tablet
PDF Leaflet Revision Date: 07/02/2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various malignancies including CML and GIST.
Dosage (summary)
400 mg/day for chronic phase CML; 600 mg/day for Ph+ ALL.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding not advised.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Warfarin
Contraindications
- Hypersensitivity to imatinib
- Pregnancy
Common side effects
- Nausea
- Diarrhoea
- Fatigue
- Fluid retention
Counselling Points
- Take with food and water
- Monitor for signs of fluid retention
- Use contraception during treatment
Serious warnings
- Hepatotoxicity
- Fluid retention
- Cardiac dysfunction
Important Disclaimer
The Imatinib 100 & 400 Zydus 100 mg, 400 mg Tablet professional information leaflet below is the property of Zydus Healthcare Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
